NewAmsterdam 计划将研究结果提交全球药品监管机构，期望未来能将 Obicetrapib 与 Ezetimibe 的固定剂量组合正式推向市场。而这些实验数据，将会在医学会议上继续被分享，进而发表于著名医学期刊。

Ezetimibe reduces LDL cholesterol levels, and niacin raises HDL cholesterol levels; however, no previous studies have described the use of these two drugs in combination. Jelesoff and colleagues ...

Get detailed information on Ezetimibe and Simvastatin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

NewAmsterdam Pharma (NAMS) stock falls as Wall Street reacts to Phase 3 data for its oral anti-cholesterol therapy. Read more ...

Discover all the brand names or Trade names of generic drug called Ezetimibe. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...

NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...

Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of ...

The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol ...

(RTTNews) - NewAmsterdam Pharma Co. N.V. (NAMS), Wednesday announced positive data from Phase 3 TANDEM clinical trial, evaluating the fixed-dose combination of 10 mg Obicetrapib and 10 mg Ezetimibe.